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It is known that thrombophilia (TP) is a risk factor for deep venous thrombosis (DVT), and that DVT predisposes to chronic
venous ulceration (CVU). However, the relationship between TP and CVU has not been well studied. Review of the
literature reveals that the prevalence of TP in CVU patients is high ± similar to the prevalence found in patients with a
history of DVT. This is despite many patients with CVU having no clear history, or duplex evidence of previous DVT. TP
may predispose to CVU by leading to macro- or micro-vascular thrombosis. This association raises several issues regarding
the investigation, prevention and management of patients with venous disease.
Eur J Vasc Endovasc Surg 24, 97±104 (2002)
doi:10.1053/ejvs.2002.1683, available online at http://www.idealibrary.com onIntroduction
Chronic venous ulceration (CVU) affects at least
1% of the adult population (life-time risk), is asso-
ciated with a marked reduction in quality of life, is
characterized by low healing and high recurrence
rates regardless of treatment, and consumes 1±2% of
health care spending in most developed countries.1±4
The pathogenesis of the condition, especially at the
microvascular level, remains incompletely defined
and controversial. However, at the macrovascular
level, it is generally agreed that the skin changes of
chronic venous insufficiency (CVI) are predominantly
due to sustained ambulatory venous hypertension.
This, in turn, is due to venous reflux in the superficial
and/or deep venous systems and, to a lesser extent,
deep venous obstruction. A significant proportion of
ulcers follow a clinically apparent and clearly docu-
mented episode of deep venous thrombosis (DVT)
(post-thrombotic syndrome). Almost certainly, a fur-
ther significant proportion of CVU follows a sub-clin-
ical, forgotten, undocumented or unrecognised DVT.
As a result, the proportion of CVU that are deemed to
be post-thrombotic varies considerably between series
depending upon thoroughness with which previous
DVT is sought.Please address all correspondence to: A. W. Bradbury, University
Department of Vascular Surgery, Lincoln House (Research Insti-
tute), Birmingham Heartlands Hospital, Bordesley Green East,
Birmingham, B9 5SS, U.K.
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mality of the clotting and/or fibrinolytic cascade(s)
that leads to a hypercoagulable state.3,5,6 TP can be
acquired or inherited and may predispose to atypical
and/or recurrent arterial and/or venous thrombosis
at a relatively young age (Table 1). As DVT is clearly a
major risk factor for CVU it is perhaps surprising
that the possible link between TP and CVU has not
received more attention. It seems reasonable to hypo-
thesise that a DVT developing in the presence of TP is
more likely to lead to the post-phlebitic syndrome and
CVU because it may occur earlier in life,7 is more likely
to be extensive, may be more resistant to endogenous
fibrinolysis and recanalisation, may be less responsive
to treatment and is more likely to recur. Furthermore,
CVU is associated with microvascular thrombosis and
the development of a peri-capillary fibrin cuff; both of
which may reflect defective fibrinolytic capacity. The
aim of this paper is to review what is known of the
relationship between CVU and TP.
Methods
The Medline database was searched for articles using
the terms: thrombophilia, venous ulceration, venous
insufficiency, as well as the individual thrombophilias.
All abstracts were reviewed, and full text of relevant
articles retrieved. Reference lists of retrieved articles
were also searched for pertinent publications.l rights reserved.
Table 1. The prevalence of thrombophilia and the relative risk for venous thrombosis.
Thrombophilia Estimated prevalence




with a first DVT (%)
Estimated relative
risk for DVT
Antithrombin III deficiency 0.2 1 5.0
Protein C deficiency 0.2 3 6.5
Protein S deficiency 1 3 2.5
Activated protein C resistance 510 21 6.5
Factor V Leiden 5±10 20 5.0
Hyperhomocystinaemia 5 11 2.5
Elevated factor VIII levels 10 25 5.0
Elevated factor XI levels 10 20 2.0
Prothrombin G202210A 2.5 6 3.0
Lupus anticoagulant 5 15 3.0
Anticardiolipin antibodies 5 15 3.0
Data are based on figures presented in several recent reviews.5,8±10,12,54,55
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Thrombophilia and its relationship with arterial and
venous thrombosis has been extensively reviewed
elsewhere.5,8±11 For that reason, only a short descrip-
tion of the common abnormalities to be discussed
below in relation to CVU is given here.12
Antithrombin (AT) deficiency
AT is synthesized by the liver and inhibits thrombin
and the activated factors of the intrinsic cascade (Xa,
IXa, XIa, XIIa) and kallikrein. Many (480) mutations
of the AT gene have been reported. AT deficiency is
usually inherited in an autosomal dominant manner.
Type I deficiency is due to low levels of AT and type II
is due to the presence of a variant AT protein. In either
case, functional AT activity can be determined by its
ability to inhibit Xa in a heparin cofactor assay. Other
tests can be used to distinguish type I from type II
deficiency, as well as different types of type II defi-
ciency. However, the clinical significance of this is
unclear and a functional test is recommended for
screening. Acquired AT deficiency can occur in asso-
ciation with many conditions including major surgery
and malignancy.5
Protein C (PC) deficiency
Protein C (PC) is a vitamin K dependent glycoprotein
that is synthesised in the liver. Protein C is activated
by the thrombin-thrombomodulin (T-TM) complex on
the surface of endothelial cells (EC). Activated PC
(APC) inhibits membrane-bound Va and VIIIa. More
than 160 mutations have been described leading to
type I and type II deficiencies. Again, a functionalEur J Vasc Endovasc Surg Vol 24, August 2002test is required for screening. This can be a synthetic
chromogenic substrate assay or a coagulation-based
assay founded on the ability of APC to prolong the
activated partial thromboplastin time (APTT).
Protein S (PS) deficiency
Protein S (PS) is a vitamin K dependent glycoprotein
that is synthesised in the liver. Approximately 60%
is bound to complement (C4b) and 40% circulates
as free protein. Only free PS acts as a non-enzymatic
cofactor to enhance the actions of APC on Va and
VIIIa. At least 70 mutations have been identified
leading to type I and type II deficiencies, which are
usually passed on in an autosomal dominant manner.
Some patients have low functional PS activity but no
identifiable mutation; either the relevant mutations is
yet to be identified or another mechanism is respon-
sible. This, so-called, type III deficiency is associated
with normal total PS antigen but reduced free antigen
and activity. Type I and type III deficiencies may co-
exist in the same kindred. There is overlap in free PS
levels between PS deficient heterozygotes and the nor-
mal population. Also, PS levels vary with age, gender,
a number of medical conditions, pregnancy and hor-
mone usage. For all these reasons, the diagnosis of PS
deficiency is more difficult than for AT or PC.
Activated protein C resistance (APCR) and
factor V leiden (FVL)
Activated PC resistance (APCR) is caused in the
great majority (90%) of cases by a single base (Leiden)
mutation in the factor V gene (FVL).13 This muta-
tion renders Va resistant to the action of APC. Other
factor V mutations (Cambridge, Hong Kong) and
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bodies (APLA), account for the remaining cases of
APCR. FVL is common in Europeans (5±10%), uncom-
mon in people from North India and the Middle East
and absent in the indigenous people of Asia, America
and Australasia. FVL heterozygotes may have a sur-
vival advantage through a reduction in intra- and
post-partum haemorrhage. The commonest test for
APCR involves measuring the prolongation of the
APTT following the addition of APC (APC ratio).
However, there are a number of problems associated
with using this test as a screening tool and most auth-
orities also recommend a polymerase chain reaction
(PCR)-based `` genetic'' test to specifically identify
the FVL mutation.12
Hyperhomocystinaemia
Hyperhomocystinaemia (HHcy) has been implicated
in the development of arterial and venous thrombosis
through a range of incompletely understood mech-
anisms.14±16 Homocysteine is a metabolic breakdown
product of methionine, which is itself metabolised
through remethylation (vitamin B12 dependent) or
transulphuration (B6 dependent) pathways. HHcy,
due to a heterozygous deficiency of one of several
enzymes involved in these pathways, is present in
approximately 1% of the population. More commonly,
HHcy is due to a deficiency of B12, B6 and folate in the
diet. Such HHcy is frequently defined as 415 mmol/l;
this being the level found in about 5% of the popula-
tion. Hcy can be measured in number of different
ways; in our laboratory we use high-pressure liquid
chromatography.
Elevated factor VIII levels
Elevated factor VIII (FVIII) levels (4150 IU/dl) are
associated with an almost five fold increase in DVT
risk and are present in just over 10% of the normal
population. Affected patients are particularly prone
to recurrent thrombosis.17 The reasons for high FVIII
are unclear but there does appear to be a hereditary
component, possibly linked to the X-chromosome.18
FVIII can also arise as part of an acute phase response
and it is recommended that C-reactive protein (CRP)
be measured at the same time.
Elevated factor XI levels
Factor XI (FXI) is a component of the intrinsic system
with direct procoagulant and indirect antifibrinolyticactivity.19 Elevated FXI levels (490th centile) are asso-
ciated with a doubling of thrombotic risk.20 As yet, it
is unclear whether the elevated level is due to specific
genetic mutations.
Prothrombin G20210A variant
Prothrombin is a vitamin-K dependent glycoprotein.
A single base mutation (A to G at position 20210) of
the prothrombin gene is found in approximately 1±3%
of the general European population but is rare in
people of African and Asian descent.21 The mutation
is associated with increased prothrombin blood levels
and activation, which presumably explains the
increased thrombotic risk.22 This may be due to
increased gene expression. The mutation can be read-
ily detected by means of PCR.
Antiphospholipid antibodies
There are two distinct types of APA; lupus anticoagu-
lant (LA) and anticardiolipin antibodies (ACLA).23
LAmay inhibit the T-TM complex dependent
activation of PC upon the EC surface. ACLA are com-
moner than LA in the general population and may be
IgM or IgG or, rarely, IgA molecules. IgG is generally
held to be the most pathogenic. ACLA appear to pro-
mote thrombosis through a number of different,
incompletely defined, mechanisms including stim-
ulation of platelet aggregation, inhibition of APC and
AT, and up-regulation of tissue factor. APLA are fre-
quently detected transiently in patients with auto-
immune and viral conditions and those on certain
drugs. It is recommended, therefore, that patients
positive for LA or ACLA should be retested after
a period of at least three months.
Other thrombophilias
New information regarding various putative inherited
and acquired risk factors for venous thrombosis is
accruing rapidly.
The multifactorial nature of thrombophilic risk and
its management
In an otherwise young and fit individual, heterozyg-
osity for a single inherited TP does not usually
confer a significant increase in the risk of primary or
recurrent thrombosis24 or of pulmonary embolism.25Eur J Vasc Endovasc Surg Vol 24, August 2002
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segregate and/or where they are accompanied by one
or more acquired TP, then risk of DVT can increase
dramatically.26 This is especially so in older indivi-
duals. For example, a FVL-positive women taking
hormone replacement therapy undergoing venous
surgery for a post-thrombotic CVU may present an
exceptionally high risk for recurrent thrombosis.27,28
At the present time, there are insufficient data to pro-
vide a firm evidence base for the management of
thrombophilic patients. However, it must be remem-
bered that oral anticoagulation to a target INR of
2.5 is associated with one major and 0.25 fatal hae-
morrhages per 100 patient treatment years.
The Prevalence of TP in CVU
AT, PC and PS deficiency
The first study to examine the relationship between
TP and CVU was conducted by Falanga who found
a reduction in PC activity/antigen, and/or PS antigen,
in 5 of 19 patients with lipodermatosclerosis (LDS)
and ulceration; two of which had a history of DVT.29
This led Falanga to propose PC deficiency as a pos-
sible risk factor for CVU. In subsequent correspond-
ence Salmaska suggested that as PC (PS) activation
requires the presence of TM, the decreased PC activity
found by Falanga might be due to an endothelial
cell defect related to venous hypertension rather
than an actual deficiency of PC.30 Tsutsui described
a patient with recurrent venous leg ulcers and a type II
protein S deficiency who responded to warfarin.31
Phifer identified three siblings with chronic venous
insufficiency, all of whom had AT III deficiency.
A further sibling had died aged 20 years old of pul-
monary embolism.32 More recently, however, Ribeau-
deau found that none of 35 consecutive patients
presenting with CVU (14 of which had a history of
DVT) had a deficiency in PC (antigen or activity), PS
(activity and free and total antigens) or AT antigen.33
APCR and FVL
In 1995, Munkvad and Jorgensen reported on 46
patients with CVU.34 Using a functional assay based
upon the activated partial thromboplastin time
(APTT) in the presence and absence of APC, APCR
was found in 12 (26%). Of these, 25% had a history of
DVT compared with eight of 34 (26%) without APCR
(non significant). Grossman reported on 29 consecu-
tive patients with CVU.35 APCR was first determinedEur J Vasc Endovasc Surg Vol 24, August 2002by a functional assay based upon the APTT and if
this was positive the FVL genetic test was performed.
Although APCR was found in 11 patients, only two
(7.7% overall) were found to be heterozygous for
FVL. Hafner and von Felten studied 20 consecutive
patients presenting with CVU.36 APCR was present in
four patients on the basis of the APTT test. Two of
these patients had a history of DVT compared with
four of 16 patients without APCR (non-significant).
However, the importance of performing the FVL gen-
etic test in all patients was quickly emphasised as it
is possible to be heterozygous for FVL without an
abnormality in the APTT APCR test, and not all
cases of APCR are caused by FVL.37,38
Hachenjos described a 34-year-old man who had
suffered recurrent CVU of both legs since childhood
in association with APCR due to FVL and an intermit-
tent factor XIII deficiency.39 Mitsis presented a similar
report of a 25-year-old man with recurrent DVT and
severe post-phlebitic syndrome. He was found to be
homozygous for FVL, and heterozygous for f II 20210
G-A mutation.40 Maessen-Visch found that 21 of 92
patients with healed or open ulceration (54 of which
had a history of DVT) were FVL positive (20 heterozy-
gous and one homozygous) compared with four of
53 controls (7.5%) (odds ratio 3.6, 95% CI 1.2±11.2,
p 0.03).41 Patients with FVL were more likely to
have a history of DVT (91% vs 48%, p 0.002) and,
specifically, recurrent DVT (38% vs 14%, p 0.03) and
to have had more than nine episodes of ulceration
(43% vs 16%, p 0.01). There was no relationship
between FVL and age or the results of light reflection
rheography. The authors concluded that the combin-
ation of DVT and FVL increased the risk of recurrent
CVU. Ribeadeau also looked at the prevalence of FVL
and APCR in 35 patients with CVU.33 APCR was
present in only four of 33 patients tested, of whom
one had a history of DVT. One patient with APCR,
and a previous DVT, was FVL positive and also had
IgG APLA. FVL was not detected in any patient with-
out APCR. The high prevalence of FVL in CVU
patients was confirmed by Gaber who studied 100
consecutive CVU patients.42 Of these, 53 were deemed
to have a post-thrombotic ulcer, 19 of whom had FVL
(36%); this compares with three of 47 CVU patients
with no history of thrombosis, and 5% of healthy
controls.
Prothrombin 20210A
To date, only one study has examined the prevalence
of PT 20210A. Ribeadeau found no cases in a series of
35 patients with CVU.
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Fig. 1. Prevalence of specific thrombophilias in CVU patients in the
Edinburgh-Birmingham study, in patients with a first DVT and in
the normal population.
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Three studies have examined the prevalence of APAs
in patients with CVU. Grossman studied 29 patients
presenting with CVU and found ACLA in six of
21 patients tested.35 In a series of 35 patients with
CVU, Ribeadeau found that APLA of IgG class were
present in three of 31 patients tested (one of whom
had a previous DVT) compared with two of 23 con-
trols.33 No patients had IgM class antibodies. IgG
antibodies were associated with APCR in two
patients, one of whom also had FVL. Alcaraz studied
27 CVU patients. Twelve CVU patients had APLA
(five ACLA, four LA and three both), three of whom
had a history of DVT.43 Unfortunately, none of the
above studies performed confirmatory repeat tests,
noted concomitant drug therapy or quantified the
level of antibody titre.
The Edinburgh and Birmingham Study
This was a prospective study of 88 patients with CVU
who underwent clinical assessment, duplex ultra-
sound and TP screen comprising antithrombin (AT),
protein C (PC) and S (PS), activated protein C resist-
ance (APCR), factor V Leiden (FVL), prothrombin
G20210A (PT 20210A), lupus anticoagulant (LA) and
anticardiolipin antibodies (ACA).44 There were
35 men of median age (IQR) 61 years (45±72), and
53 women of median age 76 years (69±82); and 36%
of patients had either a history or duplex evidence
suggestive of previous DVT. The following abnor-
malities were detected: 4 AT, 5 PC and 6 PS deficien-
cies, APCR 14, FVL 11, PT 20210A 3, LA 8 and ACLA
12. All abnormalities were confirmed on repeat testingat three months. The presence of TP was not signific-
antly related to previous DVT, deep reflux or disease
severity (duration of disease, total area, number of
episodes or level of pain). In this cohort, 41% of
patients had at least one abnormality on TP screening.
This is 2±30 times higher than the general population
but similar to that reported for DVT patients. In a
further study HHcy (415 mmol/l) was found in 23
(42%) of 55 patients with open CVU and four (25%)
of 16 patients with healed CVU. This compares with
5% of the normal population (Fig. 1). There was no
association between the presence, number or type of
thrombophilic abnormalities and the severity of dis-
ease or the pattern or severity of reflux on duplex.
Other Thrombophilias and CVU
At the time of writing there are no published data
regarding the prevalence of elevated coagulation fac-
tor levels, or the moieties listed in Table 2, and CVU.
However, on-going work in our own department is
addressing this area.
Discussion
The main conclusion to be drawn from the available
literature is that patients with CVU appear have a
prevalence of TP that is much higher than the general
population but similar to post-DVT patients. This
high prevalence is observed in ulcer patients with
and without a documented history of DVT. It is well
recognised that a patient-reported history of DVT is
unreliable due to false positives and negatives. In
other words, many DVTs are sub-clinical, others
are misdiagnosed and patients may confuse DVT
with other related conditions such as superficialEur J Vasc Endovasc Surg Vol 24, August 2002
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is increasingly used to image patients with CVU; and
duplex is much less sensitive at picking up minor
post-thrombotic changes in the deep veins, particular-
ly below the knee.45 It can be difficult, therefore, to
determine whether DVR in a patient with CVU is
post-thrombotic in aetiology or due to primary valvu-
lar insufficiency. The strong association between CVU
and TP, regardless of whether there is clear clinical or
duplex-based evidence of previous DVT, suggests that
a considerably greater proportion of patients than pre-
vious thought may actually have a post-thrombotic
ulcer. However, further work is required to determine
if, indeed, this is the case.
Many duplex-based studies have reported CVU
in association with apparently isolated superficial
venous reflux. But, it remains difficult to explain
why certain patients with gross superficial reflux
have pristine skin while others with lesser disease
suffer the full gamut of venous hypertensive skin
changes. There is the suspicion that some other, as
yet unrecognised factor, must be at work in such
patients. It is interesting to speculate that this add-
itional factor is distal macrovascular and/or micro-
vascular thrombosis; in many cases this may be
associated with undiagnosed TP. It may well be that
a significant proportion of patients with apparently
isolated superficial disease actually have infra-
popliteal post-thrombotic venous pathology that is
below the limit of duplex detection. In this regard it
is interesting to observe that DVT occurring in asso-
ciation with TP is more likely to be distal than prox-
imal.46 Furthermore, it is clear that DVT is associated
with the development of superficial reflux.47 This
may be post-thrombotic due to direct LSV damage
but other, as yet ill-defined, mechanisms may be
involved. It is also suggested that varicose veins may
be a risk factor for DVT, especially in older patients.48
At the level of the microcirculation, CVU patients
are recognised to have a hypercoagulable diathesis
characterised by depressed fibrinolytic activity, in-
creased red cell aggregation, endothelial cell damage,
expression of adhesion molecules and cytokine
release. In this regard it is interesting to observe that
long after the acute inflammatory phase of DVT has
passed there is evidence of chronic thrombin and
fibrin formation as manifest by PF12 and D-dimer;
and that this may predict recurrent thrombotic
events.47,49
Future Work
TP is clearly an important risk factor for a large
proportion, perhaps the great majority of CVU.Eur J Vasc Endovasc Surg Vol 24, August 2002Cross-sectional and longitudinal studies are needed
to answer several important clinical questions rela-
ting to the prevention and treatment of CVU. Is TP a
risk factor for the progression of simple varicose veins
to CVI and, eventually, ulceration? If so, would anti-
thrombotic treatment in thrombophilic patients
with uncomplicated varicose veins slow, even pre-
vent, disease progression? Should patients with DVT
in association with TP be offered more prolonged
anti-thrombotic treatment, either with Warfarin50,51
or low molecular weight heparin,52 in order to pre-
vent the development of CVU? Would long-term
anti-thrombotic treatment of thrombophlic patients
with CVU augment healing and reduce recurrence?53
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